Novo Nordisk A/S

Phase 2 showed 22% weight loss — competitive with injectable semaglutide 2.4mg (Wegovy). If Phase 3 confirms, this is the first oral with injectable efficacy. The addressable market for oral obesity treatment is 3-5x larger than injectable (convenience, needle-phobia, primary care access). $12B peak may be conservative. Amycretin combines GLP-1 + amylin — a differentiated mechanism that may show superior durability of weight loss.

Phase 3 execution risk. GI tolerability limits dose escalation. Oral bioavailability is notoriously variable for peptides. Competition from LLY orforglipron (ahead in development). If efficacy in Phase 3 is 15-18% instead of 22%, it loses the "injectable-equivalent" narrative.

FDA has moved to restrict compounded semaglutide. Supply constraints resolving means shortage exemption ends. Legal action will shut down major compounders.

Compounded semaglutide has created a $1,000/month price anchor vs $1,300+/month branded. Even if compounders are shut down, the political/public awareness of the price gap is permanent. Congress and payers now know GLP-1s can be made for a fraction of brand price. This creates: (1) IRA negotiation leverage, (2) payer pushback on formulary placement, (3) political pressure for price controls. The compounding episode may have permanently capped GLP-1 pricing power even after compounders are gone. At NVO's valuation (30x forward), even 10% pricing erosion is a major EPS hit.